Vanda Pharmaceuticals Projects 2026 Revenues Exceeding $240 Million Following Q3 Growth
Vanda Pharmaceuticals reported strong third-quarter performance, highlighted by a 24% year-over-year revenue increase. This growth was primarily driven by the sustained market momentum of Fanapt and early commercial contributions from its NEREUS launch. Additionally, the company successfully reduced operating expenses by 18% compared to the previous year. Looking ahead, management has set an ambitious full-year 2026 revenue target of greater than $240 million. This guidance is supported by upcoming product milestones, most notably the anticipated launch of BYSANTI scheduled for the fourth quarter.
Topics: earnings report operating expenses product launch revenue growth
Read the full article at Seeking Alpha
Part of the story Vanda Pharmaceuticals Projects 2026 Revenues Exceeding $240 Million Following Q3 Growth (3 articles)